LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Johnathan M. Lancaster"
  2. AU="Russo, Pierre A"
  3. AU="Zimmermann, Christopher"
  4. AU="Sanchez, Vanessa" AU="Sanchez, Vanessa"
  5. AU="Bello, Muideen"
  6. AU="Wezel, Anouk"
  7. AU="Clouston, Sean"
  8. AU="Olumade, Testimony J"
  9. AU=Wang Xinling AU=Wang Xinling
  10. AU="Donghua Chen"
  11. AU="Ioannis Seimenis"
  12. AU="Benjamin B Lindsey"
  13. AU="Mythili, S"
  14. AU="Mayer, Paul M"
  15. AU="Matthews, Anberitha T"
  16. AU="Zhou, Haikun"
  17. AU=Gentric Graldine
  18. AU=Lynn Joanne
  19. AU="Evangelou, Iliana"
  20. AU="Stryjewski, Martin E"
  21. AU="Stahnisch, Frank W."
  22. AU="Murakami, Tomoaki"
  23. AU="Mangal, Chris"
  24. AU="Hashem Koohy"
  25. AU="Taylor, Eric B"
  26. AU="Giroux, Nicholas S"
  27. AU="Carmen Avila-Casado"
  28. AU=Coke Christopher J.
  29. AU="Nascimento, José Hamilton do"
  30. AU="Parel, Philip M"
  31. AU="Sandrine Barbaux"
  32. AU="Sarkar, S."
  33. AU="Maymi, Valerie"
  34. AU="Ager, Casey"

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel ; Online: Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes

    Sharon E. Robertson / Maya Yasukawa / Douglas C. Marchion / Yin Xiong / Syeda Mahrukh Hussnain Naqvi / Tarik Gheit / Massimo Tommasino / Robert M. Wenham / Anna R. Giuliano / Johnathan M. Lancaster / Mian M. K. Shahzad

    PLoS ONE, Vol 18, Iss

    2023  Band 12

    Schlagwörter Medicine ; R ; Science ; Q
    Sprache Englisch
    Erscheinungsdatum 2023-01-01T00:00:00Z
    Verlag Public Library of Science (PLoS)
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel ; Online: Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes.

    Sharon E Robertson / Maya Yasukawa / Douglas C Marchion / Yin Xiong / Syeda Mahrukh Hussnain Naqvi / Tarik Gheit / Massimo Tommasino / Robert M Wenham / Anna R Giuliano / Johnathan M Lancaster / Mian M K Shahzad

    PLoS ONE, Vol 18, Iss 12, p e

    2023  Band 0294448

    Abstract: Introduction Currently 11 infectious agents are classified as carcinogenic but the role of infectious agents on outcomes of epithelial ovarian cancer is largely unknown. Objective To explore the association between infectious agents and ovarian cancer, ... ...

    Abstract Introduction Currently 11 infectious agents are classified as carcinogenic but the role of infectious agents on outcomes of epithelial ovarian cancer is largely unknown. Objective To explore the association between infectious agents and ovarian cancer, we investigated the prevalence of viral DNA in primary ovarian cancer tumors and its association with clinical outcomes. Methods Archived tumors from 98 patients diagnosed with high-grade serous epithelial ovarian cancer were collected between 1/1/1994 and 12/31/2010. After DNA extraction, Luminex technology was utilized to identify polymerase chain reaction-amplified viral DNA for 113 specific viruses. Demographic data and disease characteristics were summarized using descriptive statistics. We used logistic regression and Cox proportional hazards model to assess associations between tumor viral status and disease outcome and between tumor viral presence and overall survival (OS), respectively. Results Forty-six cases (45.9%) contained at least one virus. Six highly prevalent viruses were associated with clinical outcomes and considered viruses of interest (VOI; Epstein-Barr virus 1, Merkel cell polyomavirus, human herpes virus 6b, and human papillomaviruses 4, 16, and 23). Factors independently associated with OS were presence of VOI (HR 4.11, P = 0.0001) and platinum sensitivity (HR 0.21, P<0.0001). Median OS was significantly decreased when tumors showed VOI versus not having these viruses (22 vs 44 months, P<0.0001). Women <70 year old with VOI in tumors had significantly lower median OS versus age-matched women without VOI (20 vs 57 months, P = 0.0006); however, among women ≥70 years old, there was no difference in OS by tumor virus status. Conclusions The presence of a VOI was significantly associated with a lower OS. These findings may have implications for clinical management of ovarian cancer but require additional studies.
    Schlagwörter Medicine ; R ; Science ; Q
    Thema/Rubrik (Code) 616 ; 610
    Sprache Englisch
    Erscheinungsdatum 2023-01-01T00:00:00Z
    Verlag Public Library of Science (PLoS)
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel ; Online: Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors

    Daryoush Saeed-Vafa / Douglas C Marchion / Susan M McCarthy / Ardeshir Hakam / Alexis Lopez / Robert M Wenham / Sachin M Apte / Dung-Tsa Chen / Anthony M Magliocco / Johnathan M Lancaster / Brett M Reid / Jennifer B Permuth

    PLoS ONE, Vol 16, Iss 11, p e

    Associations with clinicopathological parameters and clinical outcomes.

    2021  Band 0256615

    Abstract: Loss of stromal caveolin-1 (Cav-1) is a biomarker of a cancer-associated fibroblast (CAF) phenotype and is related to progression, metastasis, and poor outcomes in several cancers. The objective of this study was to evaluate the clinical significance of ... ...

    Abstract Loss of stromal caveolin-1 (Cav-1) is a biomarker of a cancer-associated fibroblast (CAF) phenotype and is related to progression, metastasis, and poor outcomes in several cancers. The objective of this study was to evaluate the clinical significance of Cav-1 expression in invasive epithelial ovarian cancer (OvCa). Epithelial and stromal Cav-1 expression were quantified in serous OvCa and benign ovarian tissue in two, independent cohorts-one quantified expression using immunohistochemistry (IHC) and the other using multiplex immunofluorescence (IF) with digital image analysis designed to target CAF-specific expression. Cav-1 expression was significantly downregulated in OvCa stroma compared to non-neoplastic stroma using both the IHC (p = 0.002) and IF (p = 1.8x10-13) assays. OvCa stroma showed Cav-1 downregulation compared to tumor epithelium with IHC (p = 1.2x10-24). Conversely, Cav-1 expression was higher in OvCa stroma compared to tumor epithelium with IF (p = 0.002). There was moderate correlation between IHC and IF methods for stromal Cav-1 expression (r2 = 0.69, p = 0.006) whereas there was no correlation for epithelial expression (r2 = 0.006, p = 0.98). Irrespective of the staining assay, neither response to therapy or overall survival correlated with the expression level of Cav-1 in the stroma or tumor epithelium. Our findings demonstrate a loss of stromal Cav-1 expression in ovarian serous carcinomas. Studies are needed to replicate these findings and explore therapeutic implications, particularly for immunotherapy response.
    Schlagwörter Medicine ; R ; Science ; Q
    Thema/Rubrik (Code) 616
    Sprache Englisch
    Erscheinungsdatum 2021-01-01T00:00:00Z
    Verlag Public Library of Science (PLoS)
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  4. Artikel ; Online: Expression of the BAD pathway is a marker of triple-negative status and poor outcome

    Bernadette M. Boac / Forough Abbasi / Roohi Ismail-Khan / Yin Xiong / Atif Siddique / Hannah Park / Mingda Han / Daryoush Saeed-Vafa / Hatem Soliman / Brendon Henry / M. Juliana Pena / E. Clair McClung / Sharon E. Robertson / Sarah L. Todd / Alex Lopez / Weihong Sun / Susmitha Apuri / Johnathan M. Lancaster / Anders E. Berglund /
    Anthony M. Magliocco / Douglas C. Marchion

    Scientific Reports, Vol 9, Iss 1, Pp 1-

    2019  Band 14

    Abstract: Abstract Triple-negative breast cancer (TNBC) has few therapeutic targets, making nonspecific chemotherapy the main treatment. Therapies enhancing cancer cell sensitivity to cytotoxic agents could significantly improve patient outcomes. A BCL2-associated ...

    Abstract Abstract Triple-negative breast cancer (TNBC) has few therapeutic targets, making nonspecific chemotherapy the main treatment. Therapies enhancing cancer cell sensitivity to cytotoxic agents could significantly improve patient outcomes. A BCL2-associated agonist of cell death (BAD) pathway gene expression signature (BPGES) was derived using principal component analysis (PCA) and evaluated for associations with the TNBC phenotype and clinical outcomes. Immunohistochemistry was used to determine the relative expression levels of phospho-BAD isoforms in tumour samples. Cell survival assays evaluated the effects of BAD pathway inhibition on chemo-sensitivity. BPGES score was associated with TNBC status and overall survival (OS) in breast cancer samples of the Moffitt Total Cancer Care dataset and The Cancer Genome Atlas (TCGA). TNBC tumours were enriched for the expression of phospho-BAD isoforms. Further, the BPGES was associated with TNBC status in breast cancer cell lines of the Cancer Cell Line Encyclopedia (CCLE). Targeted inhibition of kinases known to phosphorylate BAD protein resulted in increased sensitivity to platinum agents in TNBC cell lines compared to non-TNBC cell lines. The BAD pathway is associated with triple-negative status and OS. TNBC tumours were enriched for the expression of phosphorylated BAD protein compared to non-TNBC tumours. These findings suggest that the BAD pathway it is an important determinant of TNBC clinical outcomes.
    Schlagwörter Medicine ; R ; Science ; Q
    Thema/Rubrik (Code) 616
    Sprache Englisch
    Erscheinungsdatum 2019-11-01T00:00:00Z
    Verlag Nature Publishing Group
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang